Skip to content

The effects of second-look endoscopy on the clinical outcomes of endoscopic therapy of esophageal varices in patients with decompensated cirrhosis-a randomized double-blinded controlled study

The effects of second-look endoscopy on the clinical outcomes of endoscopic therapy of esophageal varices in patients with decompensated cirrhosis-a randomized double-blinded controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16007963
Enrollment
Unknown
Registered
2016-02-22
Start date
2016-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal varice alone in cirrhosis

Interventions

second-look endoscopy group:second-look endoscopy and necessary intervention after 12±2 days of EVL
control group:no second-look endoscopy after EVL and discharge from hospital

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Consecutive patients with decompensated cirrhosis and esophageal varices (diameter between 1.0 cm-2.0 cm),with the age between 18-65 years old and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With liver cancer (>stage B in Barcelona Clinic Liver Cancer staging classification) or other malignancy; 2. With gastric varices or other ectopic varices; 3. With severe illness in heart, brain, lung or kidney, such as stroke, uremia, acute coronary syndrome, respiratory failure or type I hepatorenal syndrome; 4. No tolerance to endoscopy; 5. Transjugular intrahepatic portosystemic stent shunt or surgery before entry; 6. Total bilirubin>170umol/L or Child-Pugh score>13; 7. melaena or haematemesis, accompanied with requirement for >2 units of packed red blood cells in a 24-hour time period and hemodynamic instability that occurred before second-look endoscopy; 8. Without cirrhosis.

Design outcomes

Primary

MeasureTime frame
re-bleeding rate after 10-30 days of EVL;

Secondary

MeasureTime frame
mortality after 10-30 days of EVL;bleeding related mortality after 10-30 days of EVL;

Countries

China

Contacts

Public ContactAn-Jiang Wang
waj1103b@163.com+86 13627002546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026